Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?

REFERENCES

• . http://www.seer.cancer.gov/.
   Google Scholar
• Alexandrescu DT, Ichim TE, Riordan NH, Immunotherapy for melanoma: current status and perspectives. J Immunother. 2010 Jul-Aug;33(6):570–590.
   Google Scholar
• Halama N, Zoernig I, Jaeger D. Advanced malignant melanoma: immunologic and multimodal therapeutic strategies. J Oncol. 2010;2010:689–893.
   Google Scholar
• Kirkwood JM, Tarhini AA, Panelli MC, Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10;26(20):3445–3455.
   PubMed Web of Science ®Google Scholar
• Sivendran S, Glodny B, Pan M, Merad M, Saenger Y. Melanoma immunotherapy. Mt Sinai J Med. 2010 Nov-Dec;77(6):620–642.
   PubMed Web of Science ®Google Scholar
• Parmiani G, Anichini A, Fossati G. Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy? J Nat Cancer Inst. 1990 Mar 7;82(5):361–370.
   Google Scholar
• Mazzocchi A, Belli F, Mascheroni L, Vegetti C, Parmiani G, Anichini A. Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor via the T-cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients. Int J Cancer. 1994 Aug 1;58(3):330–339.
   Google Scholar
• Castelli C, Rivoltini L, Andreola G, Carrabba M, Renkvist N, Parmiani G. T-cell recognition of melanoma-associated antigens. J Cell Physiol. 2000 Mar;182(3):323–331.
   Web of Science ®Google Scholar
• Jager E, Ringhoffer M, Altmannsberger M, Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer. 1997 Apr 10;71(2):142–147.
   PubMed Web of Science ®Google Scholar
• Lee PP, Yee C, Savage PA, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun;5(6):677–685.
   PubMed Web of Science ®Google Scholar
• Bennink JR, Anderson R, Bacik I, Antigen processing: where tumor-specific T-cell responses begin. J Immunother Emphasis Tumor Immunol. 1993 Oct;14(3):202–208.
   Google Scholar
• Cochran AJ, Morton DL, Stern S, Lana AM, Essner R, Wen DR. Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol. 2001 Jun;14(6):604–608.
   Google Scholar
• Burke S, Lakshmikanth T, Colucci F, Carbone E. New views on natural killer cell-based immunotherapy for melanoma treatment. Trends Immunol. 2010 Sep;31(9):339–345.
   Google Scholar
• Paschen A, Sucker A, Hill B, Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 2009 Aug 15;15(16):5208–5215.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Felipe-Silva A, Heemskerk B, FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood. 2008 Dec 15;112(13):4953–4960.
   PubMed Web of Science ®Google Scholar
• Fujii H, Arakawa A, Kitoh A, Perturbations of both non-regulatory and regulatory FOXP3(+) T cells in patients with malignant melanoma. Br J Dermatol. 2010 Dec 27.
   Google Scholar
• Jandus C, Bioley G, Speiser DE, Romero P. Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood. Cancer Immunol Immunother. 2008 Dec;57(12):1795–1805.
   Google Scholar
• Van Belle P, Rodeck U, Nuamah I, Halpern AC, Elder DE. Melanoma-associated expression of transforming growth factor-beta isoforms. Am J Pathol. 1996 Jun;148(6):1887–1894.
   PubMed Web of Science ®Google Scholar
• Chen Q, Daniel V, Maher DW, Hersey P. Production of IL-10 by melanoma cells: examination of its role in immunosuppression mediated by melanoma. Int J Cancer. 1994 Mar 1;56(5):755–760.
   Google Scholar
• Gerlini G, Tun-Kyi A, Dudli C, Burg G, Pimpinelli N, Nestle FO. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol. 2004 Dec;165(6):1853–1863.
   PubMed Web of Science ®Google Scholar
• Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ. IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence. Mod Pathol. 2011 Feb 11.
   Google Scholar
• Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004 Oct;4(10):762–774.
   PubMed Web of Science ®Google Scholar
• Harlin H, Kuna TV, Peterson AC, Meng Y, Gajewski TF. Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct;55(10):1185–1197.
   Google Scholar
• Polak ME, Borthwick NJ, Gabriel FG, Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer. 2007 Jun 18;96(12):1879–1887.
   PubMed Web of Science ®Google Scholar
• Filipazzi PVR, Huber V, Iero M, Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients and modulation by GM-CSF-based anti-tumor vaccine. J Clin Oncol. [abstract]. 2007;25(No. 18S).
   Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008 Jul 20;26(21):3621–3630.
   PubMed Web of Science ®Google Scholar
• Ivanov VN, Partridge MA, Huang SX, Hei TK. Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis. J Cell Biochem. 2011 Feb;112(2):463–475.
   Google Scholar
• Schaefer U, Voloshanenko O, Willen D, Walczak H. TRAIL: a multifunctional cytokine. Front Biosci. 2007;12:3813–3824.
   PubMed Web of Science ®Google Scholar
• Yang W, Chen PW, Li H, Alizadeh H, Niederkorn JY. PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro. Invest Ophthalmol Vis Sci. 2008 Jun;49(6):2518–2525.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010 Jul 1;28(19):3167–3175.
   PubMed Web of Science ®Google Scholar
• Touloukian CE, Leitner WW, Topalian SL, Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000 Apr 1;164(7):3535–3542.
   Google Scholar
• Topalian SL, Rivoltini L, Mancini M, Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9461–9465.
   PubMed Web of Science ®Google Scholar
• Berson JF, Harper DC, Tenza D, Raposo G, Marks MS. Pmel17 initiates premelanosome morphogenesis within multivesicular bodies. Mol Biol Cell. 2001 Nov;12(11):3451–3464.
   PubMed Web of Science ®Google Scholar
• Hoashi T, Watabe H, Muller J, Yamaguchi Y, Vieira WD, Hearing VJ. MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem. 2005 Apr 8;280(14):14006–14016.
   Google Scholar
• Riley PA. Melanin. Int J Biochem Cell Biol. 1997 Nov;29(11):1235–1239.
   PubMed Web of Science ®Google Scholar
• Brasseur F, Rimoldi D, Lienard D, Expression of MAGE genes in primary and metastatic cutaneous melanoma. Int J Cancer. 1995 Nov 3;63(3):375–380.
   PubMed Web of Science ®Google Scholar
• Xxx. www.cancerimmunity.org.
   Google Scholar
• Van Der Bruggen P, Zhang Y, Chaux P, Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev. 2002 Oct;188:51–64.
   PubMed Web of Science ®Google Scholar
• Sensi M, Nicolini G, Zanon M, Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype. Cancer Res. 2005 Jan 15;65(2):632–640.
   Google Scholar
• Sharkey MS, Lizee G, Gonzales MI, Patel S, Topalian SL. CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation. Cancer Res. 2004 Mar 1;64(5):1595– 1599.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Lehmann F, Lethe B, A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7976–7980.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Wang X, Shofuda T, Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 2001 Feb 15;166(4):2871–2877.
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev. 2002 Oct;188:22–32.
   PubMed Web of Science ®Google Scholar
• Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996 Mar 1;183(3):725–729.
   PubMed Web of Science ®Google Scholar
• Zorn E, Hercend T. A MAGE-6-encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion. Eur J Immunol. 1999 Feb;29(2):602–607.
   Google Scholar
• Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997 Oct;9(5):684–693.
   PubMed Web of Science ®Google Scholar
• Chen YT, Gure AO, Tsang S, Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6919–6923.
   PubMed Web of Science ®Google Scholar
• Nind AP, Nairn RC, Rolland JM, Guli EP, Hughes ES. Lymphocyte anergy in patients with carcinoma. Br J Cancer. 1973 Aug;28(2):108–117.
   Google Scholar
• Saeki K, Iwasa Y. T cell anergy as a strategy to reduce the risk of autoimmunity. J Theor Biol. 2011 Feb 23.
   Google Scholar
• Taams LS, Wauben MH. Anergic T cells as active regulators of the immune response. Hum Immunol. 2000 Jul;61(7):633–639.
   PubMedGoogle Scholar
• Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine. 2004 Nov 15;23(1):97–113.
   PubMed Web of Science ®Google Scholar
• Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J Clin Oncol. 1990 Nov;8(11):1858–1867.
   PubMed Web of Science ®Google Scholar
• Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Expert Rev Vaccines. 2004 Oct;3(5):521–527.
   PubMedGoogle Scholar
• Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol. 2004 Feb 1;22(3):403–415.
   PubMed Web of Science ®Google Scholar
• Vilella R, Benitez D, Mila J, Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer. 2003 Sep 10;106(4):626–631.
   Google Scholar
• Sondak VK, Sosman JA. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine. Semin Cancer Biol. 2003 Dec;13(6):409–415.
   PubMed Web of Science ®Google Scholar
• Wolkers MC, Stoetter G, Vyth-Dreese FA, Schumacher TN. Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J Immunol. 2001 Oct 1;167(7):3577–3584.
   Google Scholar
• Copier J, Dalgleish A. Overview of tumor cell-based vaccines. Int Rev Immunol. 2006 Sep-Dec;25(5-6):297–319.
   PubMed Web of Science ®Google Scholar
• Vermorken JB, Claessen AM, van Tinteren H, Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999 Jan 30;353(9150):345–350.
   PubMed Web of Science ®Google Scholar
• Thompson PL, Dessureault S. Tumor cell vaccines. Adv Exp Med Biol. 2007;601:345–355.
   PubMed Web of Science ®Google Scholar
• Xxx. clinicaltrials.gov.
   Google Scholar
• Nollen EA, Morimoto RI. Chaperoning signaling pathways: molecular chaperones as stress-sensing ‘heat shock’ proteins. J Cell Sci. 2002 Jul 15;115(Pt 14):2809—2816.
   Google Scholar
• Todryk SM, Melcher AA, Dalgleish AG, Vile RG. Heat shock proteins refine the danger theory. Immunology. 2000 Mar;99(3):334–337.
   Google Scholar
• Schild H, Rammensee HG. gp96–the immune system's Swiss army knife. Nat Immunol. 2000 Aug;1(2):100–101.
   PubMed Web of Science ®Google Scholar
• Karapanagiotou EM, Syrigos K, Saif MW. Heat shock protein inhibitors and vaccines as new agents in cancer treatment. Expert Opin Investig Drugs. 2009 Feb;18(2):161–174.
   PubMed Web of Science ®Google Scholar
• Amato RJ. Heat-shock protein–peptide complex-96 for the treatment of cancer. Expert Opin Biol Ther. 2007 Aug;7(8):1267–1273.
   PubMed Web of Science ®Google Scholar
• Testori A, Richards J, Whitman E, Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008 Feb 20;26(6):955–962.
   PubMed Web of Science ®Google Scholar
• Yedavelli SP, Guo L, Daou ME, Srivastava PK, Mittelman A, Tiwari RK. Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model. Int J Mol Med. 1999 Sep;4(3):243–248.
   PubMed Web of Science ®Google Scholar
• Morton DL, Hsueh EC, Essner R, Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg. 2002 Oct;236(4):438–448; discussion 48–49.
   PubMed Web of Science ®Google Scholar
• Mitchell MS, Harel W, Kempf RA, Active-specific immunotherapy for melanoma. J Clin Oncol. 1990 May;8(5):856–869.
   Google Scholar
• Hsueh EC, Essner R, Foshag LJ, Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002 Dec 1;20(23):4549–4554.
   PubMed Web of Science ®Google Scholar
• Morton DL MN, Thompson JF, Kelley MC, An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol. [abstract]. 2007;25 (25, No. 18S (June 20 Supplement) 8508).
   Google Scholar
• Sondak VK, Liu PY, Tuthill RJ, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002 Apr 15;20(8):2058–2066.
   PubMed Web of Science ®Google Scholar
• Sosman JA, Unger JM, Liu PY, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol. 2002 Apr 15;20(8):2067–2075.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 2003 Aug;3(8):630–641.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Ueno H, Dhodapkar M, Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother. 2005 Sep-Oct;28(5):505–516.
   PubMed Web of Science ®Google Scholar
• Fong L, Hou Y, Rivas A, Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8809–8814.
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Riccobon A, Galassi R, Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Translational Med. 2004 Jul 30;2(1):27.
   Google Scholar
• Lesterhuis WJ, Aarntzen EH, De Vries IJ, Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol. 2008 May;66(2):118–134.
   Google Scholar
• Banchereau J, Palucka AK, Dhodapkar M, Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001 Sep 1;61(17):6451–6458.
   PubMed Web of Science ®Google Scholar
• Dubsky P, Saito H, Leogier M, IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol. 2007 Jun;37(6):1678– 1690.
   Google Scholar
• Schadendorf D, Ugurel S, Schuler-Thurner B, Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006 Apr;17(4):563–570.
   PubMed Web of Science ®Google Scholar
• Livingston PO, Calves MJ, Natoli EJ Jr. Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol. 1987 Mar 1;138(5):1524–1529.
   Google Scholar
• Fredman P, Hedberg K, Brezicka T. Gangliosides as therapeutic targets for cancer. BioDrugs. 2003;17(3):155–167.
   PubMed Web of Science ®Google Scholar
• Tai T, Paulson JC, Cahan LD, Irie RF. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc Natl Acad Sci U S A.1983 Sep;80(17):5392–5396.
   PubMed Web of Science ®Google Scholar
• Cahan LD, Irie RF, Singh R, Cassidenti A, Paulson JC. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc Natl Acad Sci U S A. 1982 Dec;79(24):7629–7633.
   PubMedGoogle Scholar
• Yamaguchi H, Furukawa K, Fortunato SR, Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci U S A. 1987 Apr;84(8):2416–2420.
   Google Scholar
• Livingston PO, Natoli EJ, Calves MJ, Stockert E, Oettgen HF, Old LJ. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A. 1987 May;84(9):2911–2915.
   Google Scholar
• Guthmann MD, Bitton RJ, Carnero AJ, Active specific immunotherapy of melanoma with a GM3 ganglioside-based vaccine: a report on safety and immunogenicity. J Immunother. 2004 Nov-Dec;27(6):442–451.
   Web of Science ®Google Scholar
• Ragupathi G, Livingston PO, Hood C, Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21. Clin Cancer Res. 2003 Nov 1;9(14):5214–5220.
   PubMed Web of Science ®Google Scholar
• Livingston PO, Wong GY, Adluri S, Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994 May;12(5):1036–1044.
   PubMed Web of Science ®Google Scholar
• Eggermont AM SS, Ruka W, Marsden J, EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results. J Clin Oncol. [abstract]. 2008;26 (May 20 suppl; abstr 9004).
   Google Scholar
• Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful? Eur J Cancer. 2009 Aug;45(12):2087–2090.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001 May 1;19(9):2370–2380.
   PubMed Web of Science ®Google Scholar
• Wallack MK, Bash JA, Leftheriotis E, Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate. Arch Surg. 1987 Dec;122(12):1460–1463.
   Google Scholar
• Wallack MK, Sivanandham M, Ditaranto K, Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg. 1997 Aug;226(2):198–206.
   PubMed Web of Science ®Google Scholar
• Hersey P, Coates AS, McCarthy WH, Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol. 2002 Oct 15;20(20):4181–4190.
   PubMed Web of Science ®Google Scholar
• Liu BL, Robinson M, Han ZQ, ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 2003 Feb;10(4):292–303.
   PubMed Web of Science ®Google Scholar
• Senzer NN, Kaufman HL, Amatruda T, Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 1;27(34):5763–5771.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Comin-Anduix B, Vujanovic L, Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother.2008 Apr;31(3):294–309.
   PubMed Web of Science ®Google Scholar
• Adamina M, Weber WP, Rosenthal R, Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules: a multi-centre phase I/II open labeled clinical trial. Contemp Clin Trials. 2008 Mar;29(2):165–181.
   Google Scholar
• Hofbauer GF, Baur T, Bonnet MC, Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res. 2008 Apr;18(2):104–111.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Lee P, Snively J, Phase I study of intranodal delivery of a plasmid DNA vaccine for patients with stage IV melanoma. Cancer. 2003 Jul 1;98(1):144–154.
   PubMed Web of Science ®Google Scholar
• Steele JC, Rao A, Marsden JR, Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma. Gene Ther. 2011 Feb 10.
   Google Scholar
• Jaeger E, Bernhard H, Romero P, Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer. 1996 Apr 10;66(2):162–169.
   PubMed Web of Science ®Google Scholar
• Marchand M, Weynants P, Rankin E, Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer. 1995 Dec 11;63(6):883–885.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998 Mar;4(3):321–327.
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ LD, Richards J, Conry RM, A phase III multi-institutional randomized study of immunization with the gp100;209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol. [abstract]. 2009;27 (CRA9011).
   Google Scholar
• O'Day SHF, McDermott DF, Weber RW, A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. J Clin Oncol. [abstract]. 2010;28(4).
   Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Rev. 2008 Apr;8(4):299–308.
   Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680.
   PubMed Web of Science ®Google Scholar
• Seigler H, Buckley CE, Sheppard LB, Horne BJ, Shingleton WW. Adoptive transfer and specific active immunization of patients with malignant melanoma. Ann N Y Acad Sci. 1976;277(00):522–532.
   Google Scholar
• Goff SL, Smith FO, Klapper JA, Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010 Oct;33(8):840–847.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich J, Nishimura MI, Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001 Jul-Aug;24(4):363–373.
   PubMed Web of Science ®Google Scholar
• Khammari A, Labarriere N, Vignard V, Treatment of metastatic melanoma with autologous Melan-A/MART-1-specific cytotoxic T lymphocyte clones. J Invest Dermatol. 2009 Dec;129(12):2835–2842.
   PubMed Web of Science ®Google Scholar
• Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006 Nov 1;24(31):5060–5069.
   PubMed Web of Science ®Google Scholar
• Yeh S, Karne NK, Kerkar SP, Heller CK, Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009 May;116(5):981–989 e1.
   PubMed Web of Science ®Google Scholar
• Dreno B, Nguyen JM, Khammari A, Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. 2002 Nov;51(10):539–546.
   Google Scholar
• Rosenberg SA, Dudley ME. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639–14645.
   Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (New York, NY). 2002 Oct 25;298(5594):850–854.
   Google Scholar
• Muranski P, Boni A, Wrzesinski C, Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol. 2006 Dec;3(12):668–681.
   PubMedGoogle Scholar
• Rosenberg SA, Aebersold P, Cornetta K, Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990 Aug 30;323(9):570–578.
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Gilham DE, Debets R, Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Therapy. 2010 Jun;21(6):665–672.
   Google Scholar
• Rosenberg SA, Yannelli JR, Yang JC, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Nat Cander Inst. 1994 Aug 3;86(15):1159–1166.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002 May-Jun;25(3):243–251.
   PubMed Web of Science ®Google Scholar
• Yee C, Thompson JA, Byrd D, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168– 16173.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (New York, NY). 2006 Oct 6;314(5796):126–129.
   Google Scholar
• Robbins PF, Morgan RA, Feldman SA, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 1;29(7):917–924.
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Treves AJ, Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010 May 1;16(9):2646–2655.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Dudley ME, Wunderlich J, Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004 Dec 15;173(12):7125–7130.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol. 2006 Nov 1;177(9):6527–6539.
   PubMed Web of Science ®Google Scholar
• Heemskerk B, Liu K, Dudley ME, Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Therapy. 2008 May;19(5):496–510.
   Google Scholar
• Berry LJ, Moeller M, Darcy PK. Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens. 2009 Oct;74(4):277–289.
   PubMedGoogle Scholar
• Johnson LA, Morgan RA, Dudley ME, Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009 Jul 16;114(3):535–546.
   PubMed Web of Science ®Google Scholar
• Baker PE, Gillis S, Ferm MM, Smith KA. The effect of T cell growth factor on the generation of cytolytic T cells. J Immunol.1978 Dec;121(6):2168–2173.
   Google Scholar
• Gillis S, Smith KA. Long term culture of tumour-specific cytotoxic T cells. Nature. 1977 Jul 14;268(5616):154–156.
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010 Aug 27;33(2):153–165.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007 Dec;8(12):1142–1148.
   PubMed Web of Science ®Google Scholar
• Bamford RN, Grant AJ, Burton JD, The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc Natl Acad Sci U S A. 1994 May 24;91(11):4940–4944.
   Web of Science ®Google Scholar
• Blattman JN, Grayson JM, Wherry EJ, Kaech SM, Smith KA, Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003 May;9(5):540–547.
   Google Scholar
• Kamimura D, Bevan MJ. Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med. 2007 Aug 6;204(8):1803–1812.
   PubMed Web of Science ®Google Scholar
• Kalia V, Sarkar S, Subramaniam S, Haining WN, Smith KA, Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity. 2010 Jan 29;32(1):91–103.
   PubMed Web of Science ®Google Scholar
• Pipkin ME, Sacks JA, Cruz-Guilloty F, Lichtenheld MG, Bevan MJ, Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity. 2010 Jan 29;32(1):79–90.
   PubMed Web of Science ®Google Scholar
• Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature. 2006 Jun 15;441(7095):890–893.
   PubMed Web of Science ®Google Scholar
• D'Souza WN, Lefrancois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol. 2003 Dec 1;171(11):5727–5735.
   Google Scholar
• D'Souza WN, Schluns KS, Masopust D, Lefrancois L. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J Immunol. 2002 Jun 1;168(11):5566–5572.
   Google Scholar
• Panelli MC, Wang E, Phan G, Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol. 2002 Jun 25;3(7): RESEARCH0035.
   PubMed Web of Science ®Google Scholar
• Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6(11):1142–1151.
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006 Mar 1;24(7):1169–1177.
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Mandic M, Kirkwood JM, Storkus WJ, Lotze MT. Focus on FOCIS: interleukin 2 treatment associated autoimmunity. Clin Immunol. 2008 May;127(2):123–129.
   Google Scholar
• Eton O, Rosenblum MG, Legha SS, Phase I trial of subcutaneous recombinant human interleukin-2 in patients with metastatic melanoma. Cancer. 2002 Jul 1;95(1):127–134.
   Google Scholar
• Kundig TM, Shahinian A, Kawai K, Duration of TCR stimulation determines costimulatory requirement of T cells. Immunity. 1996 Jul;5(1):41–52.
   Google Scholar
• Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med. 1996 Jul 1;184(1):1–8.
   Google Scholar
• Inozume T, Hanada K, Wang QJ, Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010 Nov-Dec;33(9):956–564.
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Atkins MB. Cytokine therapy in melanoma. J Cutan Pathol. 2010 Apr;37 Suppl 1:60–67.
   Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. Jama 1994 Mar 23-30;271(12):907–913.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999 Jul;17(7):2105–2116.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987 Apr 9;316(15):889–897.
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008 Sep 1;14(17):5610–5618.
   PubMed Web of Science ®Google Scholar
• Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev. 2007 Aug;33(5):484–496.
   Google Scholar
• Keilholz U, Conradt C, Legha SS, Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998 Sep;16(9):2921–2929.
   Google Scholar
• Rosenberg SA, Lotze MT, Yang JC, Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Nat Cancer Inst. 1993 Apr 21;85(8):622–632.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Fisher RI, Sunderland M, Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993 Oct;11(10):1969–1977.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Rosenberg SA. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. J Immunother. 2002 Mar-Apr;25(2):185–187.
   Google Scholar
• Agarwala SS, Glaspy J, O'Day SJ, Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 1;20(1):125–133.
   PubMed Web of Science ®Google Scholar
• Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996 Jan 1;77(1):89–96.
   PubMed Web of Science ®Google Scholar
• Dillman RO, O'Connor AA, Simpson L, Barth NM, VanderMolen LA, Vanderplas P. Does continuous-infusion interleukin-2 increase survival in metastatic melanoma? Am J Clin Oncol. 2003 Apr;26(2):141–145.
   Google Scholar
• Enk AH, Nashan D, Rubben A, Knop J. High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer. 2000 May 1;88(9):2042–2046.
   Google Scholar
• Pfohler C, Steinhauser S, Wagner A, Ugurel S, Tilgen W. [Complete remission of cutaneous satellite and in-transit metastases: after intralesional therapy with interleukin-2 in 2 patients with malignant melanoma]. Hautarzt. 2004 Feb;55(2):171–175.
   Google Scholar
• Weide B, Eigentler TK, Pflugfelder A, Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. Cancer Immunol Immunother. 2010 Dec 21.
   Google Scholar
• Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol. 1984 Apr;2(4):336–352.
   PubMed Web of Science ®Google Scholar
• Bremers AJ, Parmiani G. Immunology and immunotherapy of human cancer: present concepts and clinical developments. Crit Rev Oncol Hematol. 2000 Apr;34(1):1–25.
   Google Scholar
• Tompkins WA. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action. J Interferon Cytokine Res. 1999 Aug;19(8):817–828.
   Google Scholar
• Caraglia M, Marra M, Pelaia G, Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005 Feb;202(2):323–335.
   PubMed Web of Science ®Google Scholar
• Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34–55.
   PubMed Web of Science ®Google Scholar
• Critchley-Thorne RJ, Simons DL, Yan N, Impaired interferon signaling is a common immune defect in human cancer. Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9010–9015.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan;14(1):7–17.
   PubMed Web of Science ®Google Scholar
• Creagan ET, Dalton RJ, Ahmann DL, Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995 Nov;13(11):2776–2783.
   PubMed Web of Science ®Google Scholar
• Pehamberger H, Soyer HP, Steiner A, Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol. 1998 Apr;16(4):1425–1429.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Suciu S, Santinami M, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet. 2008 Jul 12;372(9633):117–126.
   PubMed Web of Science ®Google Scholar
• Gogas H, Ioannovich J, Dafni U, Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16;354(7):709–718.
   PubMed Web of Science ®Google Scholar
• Cameron DA, Cornbleet MC, Mackie RM, Adjuvant interferon alpha 2b in high risk melanoma—the Scottish study. Br J Cancer. 2001 May 4;84(9):1146–1149.
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001 Sep 15;358(9285):866-869.
   Google Scholar
• Cascinelli N, Bufalino R, Morabito A, Mackie R. Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994 Apr 9;343(8902):913–914.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Dreno B, de la Salmoniere P, Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet. 1998 Jun 27;351(9120):1905–1910.
   PubMed Web of Science ®Google Scholar
• Hancock BW, Wheatley K, Harris S, Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004 Jan 1;22(1):53–61.
   PubMedGoogle Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun;18(12):2444–2458.
   PubMed Web of Science ®Google Scholar
• Hansson J, Aamdal S, Bastholt L, Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol. 2011 Feb;12(2):144–152.
   PubMed Web of Science ®Google Scholar
• Garbe C, Radny P, Linse R, Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol. 2008 Jun;19(6):1195–1201.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Nat Cancer Inst. 2010 Apr 7;102(7):493–501.
   PubMed Web of Science ®Google Scholar
• Pectasides D, Dafni U, Bafaloukos D, Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009 Feb 20;27(6):939–944.
   Google Scholar
• Kudchadkar R, Sondak V. Adjuvant interferon: recommit or move on? Lancet Oncol. 2011 Feb;12(2):112–113.
   Google Scholar
• Peluso I, Fantini MC, Fina D, IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol. 2007 Jan 15;178(2):732–739.
   PubMed Web of Science ®Google Scholar
• Moroz A, Eppolito C, Li Q, Tao J, Clegg CH, Shrikant PA. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol. 2004 Jul 15;173(2):900–909.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol. 2002 Nov;72(5):856–863.
   PubMed Web of Science ®Google Scholar
• Ugai S, Shimozato O, Kawamura K, Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther. 2003 Mar;10(3):187–192.
   Google Scholar
• Petrella TM TR, Belanger K, Savage KJ, Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM). J Clin Oncol. [abstract]. 2010;28.
   Google Scholar
• Davis D BB, Kefford R, Millward MJ, Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: clinical data from a phase IIa study. J Clin Oncol. [abstract]. 2010;26(may20 suppl;abstr 3042).
   Google Scholar
• Schmidt H, Brown J, Mouritzen U, Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res. 2010 Nov 1;16(21):5312–5319.
   Google Scholar
• Thompson JA, Curti BD, Redman BG, Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2008 Apr 20;26(12):2034–2039.
   PubMed Web of Science ®Google Scholar
• Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1998 Dec 15;92(12):4491–4508.
   PubMed Web of Science ®Google Scholar
• Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J Immunol. 1997 Jul 15;159(2):770–776.
   PubMed Web of Science ®Google Scholar
• Szabolcs P, Moore MA, Young JW. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alpha. J Immunol. 1995 Jun 1;154(11):5851–5861.
   PubMed Web of Science ®Google Scholar
• Grabstein KH, Urdal DL, Tushinski RJ, Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (New York, NY). 1986 Apr 25;232(4749):506–508.
   Google Scholar
• Burke JM. GM-CSF-armed, replication-competent viruses for cancer. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):149–151.
   Google Scholar
• Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. 2008 Apr;222:287–298.
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS, Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000 Apr;18(8):1614–1621.
   PubMed Web of Science ®Google Scholar
• Spitler LE, Weber RW, Allen RE, Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother. 2009 Jul-Aug;32(6):632–637.
   PubMed Web of Science ®Google Scholar
• Lawson D, Kirkwood JM. Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol. 2000 Apr;18(8):1603–1605.
   Google Scholar
• Dillman RO, Selvan SR, Schiltz PM, Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm. 2009 Jun;24(3):311–319.
   PubMed Web of Science ®Google Scholar
• Faries MB, Hsueh EC, Ye X, Hoban M, Morton DL. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009 Nov 15;15(22):7029–7035.
   PubMed Web of Science ®Google Scholar
• Pilla L, Patuzzo R, Rivoltini L, A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunol Immunother. 2006 Aug;55(8):958–968.
   PubMed Web of Science ®Google Scholar
• Slingluff CL Jr, Petroni GR, Olson WC, Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009 Nov 15;15(22):7036–7044.
   PubMed Web of Science ®Google Scholar
• Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007 Feb;18(2):226–232.
   PubMed Web of Science ®Google Scholar
• Jager E, Ringhoffer M, Dienes HP, Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer. 1996 Jul 3;67(1):54–62.
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Schmittel A, Keilholz U, Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother. 2000 Mar-Apr;23(2):275–281.
   PubMed Web of Science ®Google Scholar
• Daud AI, Mirza N, Lenox B, Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol. 2008 Jul 1;26(19):3235–3241.
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004 Dec;4(12):941–952.
   PubMed Web of Science ®Google Scholar
• Rossner S, Voigtlander C, Wiethe C, Hanig J, Seifarth C, Lutz MB. Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro. Eur J Immunol. 2005 Dec;35(12):3533–3544.
   Google Scholar
• Srivastava S, Salim N, Robertson MJ. Interleukin-18: biology and role in the immunotherapy of cancer. Curr Med Chem. 2010;17(29):3353–3357.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Millward M, Mainwaring P, A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15;115(4):859–868.
   Google Scholar
• Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am. 1998 Aug;12(4):877–902, viii.
   Google Scholar
• Schiller JH, Pugh M, Kirkwood JM, Karp D, Larson M, Borden E. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996 Jan;2(1):29–36.
   PubMed Web of Science ®Google Scholar
• Rossi CR, Pasquali S, Mocellin S, Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol. 2010 Nov;17(11):3000–3007.
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF, A new member of the immunoglobulin superfamily—CTLA-4. Nature. 1987 Jul 16-22;328(6127):267–270.
   PubMed Web of Science ®Google Scholar
• Greene JL, Leytze GM, Emswiler J, Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J Biol Chem. 1996 Oct 25;271(43):26762–26771.
   Google Scholar
• Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science (New York, NY). 1993 Nov 5;262(5135):905–907.
   Google Scholar
• Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 1991 Sep 1;174(3):561–569.
   PubMed Web of Science ®Google Scholar
• Powrie F, Read S, Mottet C, Uhlig H, Maloy K. Control of immune pathology by regulatory T cells. Novartis Found Symp. 2003;252:92–98; discussion 8-105, 6-14.
   PubMedGoogle Scholar
• Maker AV, Phan GQ, Attia P, Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec;12(12):1005–1016.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (New York, NY). 1996 Mar 22;271(5256):1734–1736.
   Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999 Aug 2;190(3):355– 366.
   PubMed Web of Science ®Google Scholar
• van Elsas A, Sutmuller RP, Hurwitz AA, Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med. 2001 Aug 20;194(4):481–489.
   PubMed Web of Science ®Google Scholar
• Bulanhagui CA AR D. Pavlov, V., Bozon, A., Sharma, J., Gomez-Navarro, L. Camacho Phase I clinical trials of ticilimumab: tumor responses are sufficient but not necessary for prolonged survival. J Clin Oncol. 2006 ASCO Annual Meeting Proceedings Part I. [Abstract]. June 20, 2006;24(18S).
   Google Scholar
• Ribas A, Camacho LH, Lopez-Berestein G, Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10;23(35):8968–8977.
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B, Lee Y, Jalil J, Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Translational Med. 2008;6:22.
   Google Scholar
• Beck KE, Blansfield JA, Tran KQ, Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 May 20;24(15):2283–2289.
   PubMed Web of Science ®Google Scholar
• von Euw E, Chodon T, Attar N, CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Translational Med. 2009;7:35.
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J, Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009 Mar 1;27(7):1075–1081.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lorigan P, Hersey P, Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010 Feb 1;16(3):1042– 1048.
   PubMed Web of Science ®Google Scholar
• Ribas A, Comin-Anduix B, Chmielowski B, Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 1;15(19):6267– 6276.
   PubMed Web of Science ®Google Scholar
• Tarhini AA MS, Schlesselman JJ, Shope-Spotloe J, Demark M, Kirkwood JM. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma. J Clin Oncol. [abstract]. 2008;26(abstr 9009).
   Google Scholar
• Underhill C MM, Lobb S, McBurnie J, Phase I dose escalation trial of tremelimumab (CP-675,206) administered in combination with PF-3512676 in patients with melanoma or other advanced cancers. J Clin Oncol. [abstract]. 2009;27(suppl; abstr 3046).
   Google Scholar
• Ribas A HA, Kefford R, Punt CJ, Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol. [Abstract]. 2008 May 20, 2008;26.
   Google Scholar
• Hamid O CK, Li J, Neyns B, Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. J Clin Oncol. [Abstract]. 2008;26(No 15S (May 20 Supplement), 9025.
   Google Scholar
• Hersh EM, O'Day SJ, Powderly J, A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. 2010 Jan 16.
   Google Scholar
• Phan GQ, Yang JC, Sherry RM, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372–8377.
   PubMed Web of Science ®Google Scholar
• Tchekmedyian S GJ, Korman A, Keler T, Deo Y, Davis TA. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc Am Soc Clin Oncol [abstract]. 2002;21(abstract 56).
   Google Scholar
• Weber JS BD, Siegel J, Minor D, Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol. [abstract]. 2008;26(abstr 9010).
   Google Scholar
• O'Day SJ IR, DePril V, Maio M, Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol. [abstract]. 2008;26(abstr 9021).
   Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004 May;20(5):529–538.
   PubMed Web of Science ®Google Scholar
• Larrubia JR, Benito-Martinez S, Miquel J, Calvino M, Sanz-de-Villalobos E, Parra-Cid T. Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. World J Gastroenterol. 2009 Nov 7;15(41):5129–5140.
   Google Scholar
• Brahmer JR TS, Powderly J, Wollner I, Phase II experience with MDX-1106 (Ono-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol. [abstract]. 2009 (suppl; abstr 3018):27:15s.
   Google Scholar
• Hofmann MA, Kors C, Audring H, Walden P, Sterry W, Trefzer U. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. 2008 Jun;31(5):520–527.
   PubMedGoogle Scholar
• Leonard JP, Link BK, Emmanouilides C, Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res. 2007 Oct 15;13(20):6168–6174.
   PubMedGoogle Scholar
• Pashenkov M, Goess G, Wagner C, Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006 Dec 20;24(36):5716–5724.
   PubMed Web of Science ®Google Scholar
• Weber JS, Zarour H, Redman B, Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer. 2009 Sep 1;115(17):3944–3954.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol. 2011;707:3–17.
   Google Scholar
• Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol. 2003 Dec 15;171(12):6323–6327.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005 Apr;6(4):345–352.
   PubMed Web of Science ®Google Scholar
• Liu W, Putnam AL, Xu-Yu Z, CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006 Jul 10;203(7):1701–1711.
   PubMed Web of Science ®Google Scholar
• McCarter MD, Baumgartner J, Escobar GA, Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct;14(10):2854–2860.
   Google Scholar
• Yokokawa J, Cereda V, Remondo C, Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res. 2008 Feb 15;14(4):1032–1040.
   PubMed Web of Science ®Google Scholar
• Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009 Oct 1;125(7):1640–1648.
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaitre F, Verola O, Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol. 2004 Jul 15;173(2):1444–1453.
   PubMed Web of Science ®Google Scholar
• Nicholaou T, Ebert LM, Davis ID, Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009 Mar 15;15(6):2166–2173.
   PubMed Web of Science ®Google Scholar
• Baumgartner JM, Gonzalez R, Lewis KD, Increased survival from stage IV melanoma associated with fewer regulatory T Cells. J Surg Res. 2009 Jun 1;154(1):13–20.
   Google Scholar
• Jacobs JF, Punt CJ, Lesterhuis WJ, Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin Cancer Res. 2010 Oct 15;16(20):5067–5078.
   PubMed Web of Science ®Google Scholar
• Powell DJ Jr, Attia P, Ghetie V, Schindler J, Vitetta ES, Rosenberg SA. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother. 2008 Feb-Mar;31(2):189–198.
   Google Scholar
• Powell DJ Jr, Felipe-Silva A, Merino MJ, Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007 Oct 1;179(7):4919–4928.
   PubMed Web of Science ®Google Scholar
• Kong LY, Wei J, Sharma AK, A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul;58(7):1023–1032.
   PubMed Web of Science ®Google Scholar
• Mahnke K, Schonfeld K, Fondel S, Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer. 2007 Jun 15;120(12):2723–2733.
   PubMed Web of Science ®Google Scholar
• de Vries IJ, Castelli C, Huygens C, Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents. Clin Cancer Res. 2011 Feb 15;17(4):841–848.
   Google Scholar
• Wilgenhof SVNA, Benteyn D, Pierret L, Therapeutic vaccination with an autologous TriMix–dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma. J Clin Oncol. [abstract]. 2009;27(9024).
   Google Scholar
• Lacelle MG, Jensen SM, Fox BA. Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin Cancer Res. 2009 Nov 15;15(22):6881–6890.
   Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003 Jul-Aug;26(4):332–342.
   PubMed Web of Science ®Google Scholar
• Adler MJ, White CR Jr. Amelanotic malignant melanoma. Semin Cutan Med Surg. 1997 Jun;16(2):122–130.
   Google Scholar
• Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Nat Cancer Inst. 1996 Jan 17;88(2):100–108.
   PubMed Web of Science ®Google Scholar
• Lee KH, Panelli MC, Kim CJ, Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol. 1998 Oct 15;161(8):4183– 4194.
   Google Scholar
• Nishitani N, Bito T, Ikeda T, Tokura Y, Nishigori C. Complete remission of metastatic malignant melanoma after surgery in association with development of systemic vitiligo. J Dermatol. 2010 Aug;37(8):770–772.
   Google Scholar
• Branum GD, Seigler HF. Role of surgical intervention in the management of intestinal metastases from malignant melanoma. Am J Surg. 1991 Nov;162(5):428–431.
   Google Scholar
• Gorenstein LA, Putnam JB, Natarajan G, Balch CA, Roth JA. Improved survival after resection of pulmonary metastases from malignant melanoma. Ann Thorac Surg. 1991 Aug;52(2):204–10.
   Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 1;23(10):2346–2357.
   PubMed Web of Science ®Google Scholar
• Khammari A, Nguyen JM, Pandolfino MC, Long-term follow-up of patients treated by adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother. 2007 Nov;56(11):1853–1860.
   PubMed Web of Science ®Google Scholar
• Pandolfi F, Boyle LA, Trentin L, Kurnick JT, Isselbacher KJ, Gattoni-Celli S. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. Cancer Res. 1991 Jun 15;51(12):3164–3170.
   Google Scholar
• Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich Hurley C. Frequencies of HLA-A2 alleles in five U.S. population groups; predominance of A*02011 and identification of HLA-A*0231. Hum Immunol. 2000 Mar;61(3):334–340.
   PubMed Web of Science ®Google Scholar
• Benlalam H, Labarriere N, Linard B, Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy. Eur J Immunol. 2001 Jul;31(7):2007–2015.
   PubMed Web of Science ®Google Scholar
• Labarriere N, Pandolfino MC, Raingeard D, Frequency and relative fraction of tumor antigen-specific T cells among lymphocytes from melanoma-invaded lymph nodes. Int J Cancer. 1998 Oct 5;78(2):209–215.
   Google Scholar
• Rosenberg SA, Sherry RM, Morton KE, Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005 Nov 1;175(9):6169–6176.
   PubMed Web of Science ®Google Scholar
• Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol. 2007 Sep;7(9):737–744.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ, Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009 Feb 15;15(4):1443–1451.
   PubMed Web of Science ®Google Scholar
• Osanto S, Schiphorst PP, Weijl NI, Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Therapy. 2000 Mar 20;11(5):739–750.
   PubMed Web of Science ®Google Scholar
• Escobar A, Lopez M, Serrano A, Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005 Dec;142(3):555–568.
   PubMed Web of Science ®Google Scholar
• Chakraborty NG, Chattopadhyay S, Mehrotra S, Chhabra A, Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol. 2004 Aug;65(8):794–802.
   Google Scholar
• Rasku MA, Clem AL, Telang S, Transient T cell depletion causes regression of melanoma metastases. J Translational Med. 2008;6:12.
   PubMed Web of Science ®Google Scholar
• Olivares J, Kumar P, Yu Y, Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res. 2011 Jan 1;17(1):183–192.
   Web of Science ®Google Scholar
• Pilon-Thomas S, Mackay A, Vohra N, Mule JJ. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma. J Immunol. 2010 Apr 1;184(7):3442–3449.
   PubMedGoogle Scholar
• Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010 Aug 1;70(15):6171–6180.
   PubMed Web of Science ®Google Scholar
• Budd GT, Murthy S, Finke J, Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy. J Clin Oncol. 1992 May;10(5):804–809.
   Google Scholar
• Hidalgo OF, Aramendia JM, Alonso G, Foncillas JG, Brugarolas A. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Rev Med Univ Navarra. 1996 Jul-Sep;40(3):6–12.
   Google Scholar
• Hauschild A, Weichenthal M, Balda BR, Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003 Aug 1;21(15):2883–2888.
   Google Scholar
• Kim CJ, Taubenberger JK, Simonis TB, White DE, Rosenberg SA, Marincola FM. Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):50–58.
   Google Scholar
• Khayat D, Borel C, Tourani JM, Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993 Nov;11(11):2173–2180.
   Google Scholar
• Punt CJ, Suciu S, Gore MA, Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group. Eur J Cancer. 2006 Nov;42(17):2991–2995.
   Google Scholar
• Atkins MB, Hsu J, Lee S, Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008 Dec 10;26(35):5748–5754.
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Neuber K, Kamanabrou D, Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer. 2002 Jan 21;86(2):179–184.
   PubMed Web of Science ®Google Scholar
• Lange JR, Raubitschek AA, Pockaj BA, A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunother. (1991)1992 Nov;12(4):265–271.
   Google Scholar
• Quan WD Jr, Quan FM. Activity of continuous infusion + pulse interleukin-2 with famotidine in metastatic melanoma. Cancer Biother Radiopharm. 2009 Feb;24(1):1–6.
   Google Scholar
• Ahmed A, Wong DM, Thurman GB, T-lymphocyte maturation: cell surface markers and immune function induced by T-lymphocyte cell-free products and thymosin polypeptides. Ann N Y Acad Sci. 1979;332:81–94.
   PubMedGoogle Scholar
• Kabelitz D, Wesch D, Oberg HH. Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. Crit Rev Immunol. 2006;26(4):291–306.
   Google Scholar
• Romani L, Bistoni F, Gaziano R, Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 2004 Jun 1;103(11):4232–4239.
   PubMed Web of Science ®Google Scholar
• Sztein MB, Serrate SA. Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol. 1989;11(7):789–800.
   Google Scholar
• Maio M, Mackiewicz A, Testori A, Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol. 2010 Apr 1;28(10):1780–1787.
   PubMed Web of Science ®Google Scholar
• Berger A, Quast SA, Plotz M, Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative—enhancement of both extrinsic and intrinsic apoptosis pathways. Biochem Pharmacol. 2011 Jan 1;81(1):71–81.
   Google Scholar
• Powell DJ Jr, de Vries CR, Allen T, Ahmadzadeh M, Rosenberg SA. Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy. J Immunother. 2007 May-Jun;30(4):438–447.
   Google Scholar